Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new research note on commercial-stage specialty pharmaceutical company Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF).
Davison describes what he calls a "great partnership" between Shield and Viatris, which are working together to promote and market Accrufer, an oral treatment for iron deficiency with a very low side effect profile.